Cargando…
Alternative Routes of Administration for Therapeutic Antibodies—State of the Art
Background: For the past two decades, there has been a huge expansion in the development of therapeutic antibodies, with 6 to 10 novel entities approved each year. Around 70% of these Abs are delivered through IV injection, a mode of administration allowing rapid and systemic delivery of the drug. H...
Autores principales: | Pitiot, Aubin, Heuzé-Vourc’h, Nathalie, Sécher, Thomas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9495858/ https://www.ncbi.nlm.nih.gov/pubmed/36134952 http://dx.doi.org/10.3390/antib11030056 |
Ejemplares similares
-
Immune Checkpoint and Anti-Angiogenic Antibodies for the Treatment of Non-Small Cell Lung Cancer in the European Union and United States
por: Ferreira, Marion, et al.
Publicado: (2021) -
Therapeutic Antibodies for the Treatment of Respiratory Tract Infections—Current Overview and Perspectives
por: Mayor, Alexie, et al.
Publicado: (2021) -
Inhalation of Immuno-Therapeutics/-Prophylactics to Fight Respiratory Tract Infections: An Appropriate Drug at the Right Place!
por: Sécher, Thomas, et al.
Publicado: (2019) -
Therapeutic antibodies – natural and pathological barriers and strategies to overcome them
por: Al Ojaimi, Yara, et al.
Publicado: (2022) -
Pneumocystis Pneumonia: Pitfalls and Hindrances to Establishing a Reliable Animal Model
por: Chesnay, Adélaïde, et al.
Publicado: (2022)